RT Journal Article
SR Electronic
T1 Combined metabolic cofactor supplementation accelerates recovery in mild-to-moderate COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.02.20202614
DO 10.1101/2020.10.02.20202614
A1 Altay, Ozlem
A1 Yang, Hong
A1 Aydin, Mehtap
A1 Alkurt, Gizem
A1 Altunal, L. Nilsun
A1 Kim, Woonghee
A1 Akyol, Dogukan
A1 Arif, Muhammad
A1 Zhang, Cheng
A1 Dinler-Doganay, Gizem
A1 Turkez, Hasan
A1 Shoaie, Saeed
A1 Nielsen, Jens
A1 Borén, Jan
A1 Doganay, Levent
A1 Uhlén, Mathias
A1 Mardinoglu, Adil
YR 2020
UL http://medrxiv.org/content/early/2020/10/05/2020.10.02.20202614.abstract
AB BACKGROUND The characteristics of COVID-19 outbreak and high fatality rate of COVID□19 infection have attracted the attention of scientists due to the strong interactions between components of metabolic syndrome, metabolic abnormalities, and viral pathobiology of COVID-19. Combined metabolic cofactors supplementation (CMCS) consisting of L-serine, N-acetyl-L-cysteine (NAC), nicotinamide riboside (NR), and L-carnitine tartrate is being studied for the treatment of patients with COVID-19.METHODS We conducted a placebo-controlled, phase-2 clinical trial involving ambulatory COVID-19 patients. A total of 100 patients were randomly assigned on a 3:1 basis to hydroxychloroquine plus CMCS or hydroxychloroquine plus placebo. The total treatment period for the hydroxychloroquine was 5 days, and for the CMCS/placebo was 14 days. Clinical status was evaluated daily by phone, using a binomial scale for subject reported presence or absence for multiple COVID-19 related symptoms. Plasma samples for clinical chemistry analyses were collected on day 0 and day 14.RESULTS A total of 93 patients completed the trial. The combination of CMCS and hydroxychloroquine significantly reduced the average complete recovery time compared with hydroxychloroquine and placebo (6.6 days vs 9.3 days, respectively). Moreover, there was a significant reduction in ALT, AST and LDH levels on day 14 compared to day 0 in the hydroxychloroquine plus CMCS group. The adverse effects were uncommon and self-limiting.CONCLUSIONS In patients with mild-to-moderate COVID-19, CMCS resulted in a significant reduction in recovery time and liver enzymes associated with hepatic function compared to placebo. We observed that CMSC is associated with a low incidence of adverse events.Competing Interest StatementAM, JB and MU filed a patent application on the use of CMCS on COVID-19 patients. The other authors declare no competing interests.Clinical TrialClinicalTrials.gov NCT04573153Funding StatementThis work was supported by Knut and Alice Wallenberg Foundation. The authors would like to thank ChromaDex (Irvine, CA, USA) for providing NR for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been approved by the ethics committee of Istanbul Medipol University. Decision No:45 Decision Date: 28/05/2020 Members of Ethics Committee: Professor Hanefi OZBEK Professor Gurkan OZTURK Professor Fulya IlCin GONENC Professor Abdulbari BENER Associate Professor Ali OZTURK Associate Professor Bahri TEKER Associate Professor Muhammed Fatih EVCIMIKAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author [adilm@scilifelab.se], upon reasonable request.